R146
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 52
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.480
- MYC_TARGETS_V1+0.370
- ANDROGEN_RESPONSE+0.290
- MTORC1_SIGNALING+0.220
- UV_RESPONSE_DN+0.210
- OXIDATIVE_PHOSPHORYLATION+0.150
- GLYCOLYSIS+0.140
- UNFOLDED_PROTEIN_RESPONSE+0.140
- PANCREAS_BETA_CELLS+0.120
- TGF_BETA_SIGNALING+0.100
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.360
- IL6_JAK_STAT3_SIGNALING-0.300
- INTERFERON_GAMMA_RESPONSE-0.300
- TNFA_SIGNALING_VIA_NFKB-0.290
- MYOGENESIS-0.280
- APICAL_JUNCTION-0.270
- ESTROGEN_RESPONSE_EARLY-0.260
- KRAS_SIGNALING_DN-0.260
- P53_PATHWAY-0.260
- INFLAMMATORY_RESPONSE-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R157 | — | — | 0.864 |
| 2 | MNG363 | — | — | 0.841 |
| 3 | BS_KYF0Q0E7 | Med | Medulloblastoma | 0.809 |
| 4 | SJEPD030795_D2.RNA-Seq | EPN | Posterior Fossa EPN | 0.805 |
| 5 | R169 | — | — | 0.802 |
| 6 | MNG730 | — | — | 0.800 |
| 7 | MNG775 | — | — | 0.798 |
| 8 | TCGA-BH-A204-01A-11R-A157-07 | — | B | 0.790 |
| 9 | DRR168541 | — | — | 0.783 |
| 10 | R127 | — | — | 0.783 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.480 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.290 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.150 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.140 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.120 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.070 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.070 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.060 | Inavolisib | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.030 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.030 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.020 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.010 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.010 | Inavolisib | — uncovered |